未找到相关数据
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.
被引：0
作者：
Pelzer, Uwe
Blanc, Jean-Frederic
Melisi, Davide
Cubillo, Antonio
Von Hoff, Daniel D.
Wang-Gillam, Andrea
Chen, Li-Tzong
Siveke, Jens T.
Wan, Yin
Solem, Caitlyn T.
Botteman, Marc
Yang, Yoojung
de Jong, Floris
Hubner, Richard
机构：
[1] Charite Univ Med Berlin, Dept Hematol Oncol Tumorimmunol, Berlin, Germany
[2] Hop St Andre, Bordeaux, France
[3] Univ Verona, Digest Mol Clin Oncol, Verona, Italy
[4] Hosp Madrid Norte Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain
[5] Virginia G Piper Canc Ctr Honor Hlth, TGen, Scottsdale, AZ USA
[6] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[7] Natl Inst Canc Res, NHRI, Taipei, Taiwan
[8] Univ Hosp Essen, Div Solid Tumor Translat Oncol, West German Canc Ctr, D-45147 Essen, Germany
[9] Pharmerit Int, Bethesda, MD USA
[10] Baxalta US Inc, Cambridge, MA USA
[11] Baxalta GmbH, Zurich, Switzerland
[12] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15732
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15732
引用
收藏
页数：2
相关论文